These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 14982807)
1. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Clemons KV; Stevens DA Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807 [TBL] [Abstract][Full Text] [Related]
2. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Clemons KV; Stevens DA Antimicrob Agents Chemother; 1998 Apr; 42(4):899-902. PubMed ID: 9559804 [TBL] [Abstract][Full Text] [Related]
3. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations. Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. Clemons KV; Parmar R; Martinez M; Stevens DA J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192 [TBL] [Abstract][Full Text] [Related]
5. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y J Antimicrob Chemother; 2004 Feb; 53(2):311-7. PubMed ID: 14729753 [TBL] [Abstract][Full Text] [Related]
6. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374 [TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. Leenders AC; de Marie S; ten Kate MT; Bakker-Woudenberg IA; Verbrugh HA J Antimicrob Chemother; 1996 Aug; 38(2):215-25. PubMed ID: 8877535 [TBL] [Abstract][Full Text] [Related]
8. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Clemons KV; Schwartz JA; Stevens DA Antimicrob Agents Chemother; 2012 Aug; 56(8):4439-49. PubMed ID: 22687510 [TBL] [Abstract][Full Text] [Related]
9. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Yardley V; Croft SL Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238 [TBL] [Abstract][Full Text] [Related]
10. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414 [TBL] [Abstract][Full Text] [Related]
11. Overview of the lipid formulations of amphotericin B. Dupont B J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578 [TBL] [Abstract][Full Text] [Related]
12. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma. Henderson RJ; Leon CG; Wasan KM Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Yardley V; Croft SL Am J Trop Med Hyg; 1999 Aug; 61(2):193-7. PubMed ID: 10463666 [TBL] [Abstract][Full Text] [Related]
15. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139 [TBL] [Abstract][Full Text] [Related]
16. Amphotericin B--not so terrible. Bishara J; Weinberger M; Lin AY; Pitlik S Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528 [TBL] [Abstract][Full Text] [Related]
17. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. Ruijgrok EJ; Vulto AG; Van Etten EW J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537 [TBL] [Abstract][Full Text] [Related]
18. Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Garcia A; Adler-Moore JP; Proffitt RT Antimicrob Agents Chemother; 2000 Sep; 44(9):2327-32. PubMed ID: 10952575 [TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B therapy of murine histoplasmosis. Graybill JR; Bocanegra R Antimicrob Agents Chemother; 1995 Aug; 39(8):1885-7. PubMed ID: 7486941 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Delmas G; Park S; Chen ZW; Tan F; Kashiwazaki R; Zarif L; Perlin DS Antimicrob Agents Chemother; 2002 Aug; 46(8):2704-7. PubMed ID: 12121962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]